inclusion criteria: age ≥ 18 years old ecog performance status ≤ 2 subjects with histologically or cytologically confirmed cancer diagnosis (invasive solid tumour or haematological malignancy) undergoing active systemic cancer treatment at the time of the last dose (before icf signature) of the anti-sars-cov-2 mrna vaccine (such as chemotherapy, immunotherapy, targeted agents, endocrine therapy) in non-metastatic/curative setting or in metastatic/palliative setting or undergoing follow-up after confirmed cancer complete remission without active cancer treatment for the last 12 months at the time of the last dose (before icf signature ) of the anti-sars-cov-2 mrna vaccine. life expectancy > 6 months subjects who received at least 2 doses of mrna platform vaccination against sars-cov-2 as per local guidelines, with the last dose being given within the last 6 months (maximum until 6 months and 4 weeks) prior to baseline assessment. urine/serum pregnancy test negative for all female subjects of childbearing potential within 7 days prior to subject enrolment. signed informed consent form (icf) obtained prior to any study related procedure and obtained within 8 weeks prior to the baseline assessment subject is willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations.

inclusion criteria: age ≥ 18 years old ecog performance status ≤ 2 subjects with histologically or cytologically confirmed cancer diagnosis (invasive solid tumour or haematological malignancy) undergoing active systemic cancer treatment at the time of the last dose (before icf signature) of the anti-sars-cov-2 mrna vaccine (such as chemotherapy, immunotherapy, targeted agents, endocrine therapy) in non-metastatic/curative setting or in metastatic/palliative setting or undergoing follow-up after confirmed cancer complete remission without active cancer treatment for the last 12 months at the time of the last dose (before icf signature ) of the anti-sars-cov-2 mrna vaccine. life expectancy > 6 months subjects who received at least 2 doses of mrna platform vaccination against sars-cov-2 as per local guidelines, with the last dose being given within the last 6 months (maximum until 6 months and 4 weeks) prior to baseline assessment. urine/serum pregnancy test negative for all female subjects of childbearing potential within 7 days prior to subject enrolment. signed informed consent form (icf) obtained prior to any study related procedure and obtained within 8 weeks prior to the baseline assessment subject is willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations.

inclusion criteria: - age ≥ 18 years old - ecog performance status ≤ 2 - must have histologically or cytologically confirmed cancer diagnosis (invasive solid tumour or haematological malignancy) - currently undergoing active systemic cancer treatment (such as chemotherapy, immunotherapy, targeted agents, endocrine therapy) in non-metastatic setting or in metastatic setting (1st line therapy at the time of 1st dose of the anti-sars-cov-2 mrna vaccine) - or currently undergoing follow-up after confirmed cancer complete remission without active cancer treatment for the last 12 months - life expectancy > 6 months - received 2nd dose of mrna platform vaccination against sars-cov-2 as per local guidelines within 6 months (maximum until 6 months and 3 weeks) prior to registration. - urine pregnancy test negative for all female subjects of childbearing potential within 7 days prior to subject enrolment. - signed informed consent form (icf) obtained prior to any study related procedure. - subject is willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations.

inclusion criteria: - age ≥ 18 years old - ecog performance status ≤ 2 - must have histologically or cytologically confirmed cancer diagnosis (invasive solid tumour or haematological malignancy) - currently undergoing active systemic cancer treatment (such as chemotherapy, immunotherapy, targeted agents, endocrine therapy) in non-metastatic setting or in metastatic setting (1st line therapy at the time of 1st dose of the anti-sars-cov-2 mrna vaccine) - or currently undergoing follow-up after confirmed cancer complete remission without active cancer treatment for the last 12 months - life expectancy > 6 months - received 2nd dose of mrna platform vaccination against sars-cov-2 as per local guidelines within 6 months (maximum until 6 months and 3 weeks) prior to registration. - urine pregnancy test negative for all female subjects of childbearing potential within 7 days prior to subject enrolment. - signed informed consent form (icf) obtained prior to any study related procedure. - subject is willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations.